Zenapax is indicated for the prophylaxis of acute organ rejection in patients receiving renal transplants.
Zenapax is indicated for the prophylaxis of acute organ rejection in patients receiving renal transplants as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids.
General Information :
Hoffman-La Roche’s new monoclonal antibody drug, Zenapax (daclizumab), has been approved to prevent rejection of kidney transplants. The drug uses the body’s own immune system to prevent the acute rejection that can make kidney transplants fail.
Clinical Results. It is marketed by Hoffman La Roche pharmaceuticals.
The FDA said its approval was based on two clinical trials that showed Zenapax significantly reduced acute rejections in patients who got the drug along with the standard three-drug cocktail of immunosuppressant drugs. Patients on Zenapax had 37 to 40% fewer rejections episodes than those given an inert placebo.